← Back to headlines
STADA Group Reports Strong Growth Across All Segments in 2025
The STADA Group, which includes Hemofarm, achieved significant growth in 2025 across all three of its segments: specialty pharmaceuticals, consumer health products, and generic medicines.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Philippines Lawmakers Demand Action on Spiking Inflation and Fuel Prices
just now
MIMAROPA Drivers to Receive P5,000 Cash Aid Amid Rising Fuel Prices
just now
Philippine Ombudsman Seeks Ex-House Official's SALNs for Graft Probe
just now
Excess Sardines Spoil at Sorsogon Port Due to Holy Week Shutdowns
just now